MA55198A - Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux - Google Patents

Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux

Info

Publication number
MA55198A
MA55198A MA055198A MA55198A MA55198A MA 55198 A MA55198 A MA 55198A MA 055198 A MA055198 A MA 055198A MA 55198 A MA55198 A MA 55198A MA 55198 A MA55198 A MA 55198A
Authority
MA
Morocco
Prior art keywords
compounds useful
anticancer agents
tricyclic compounds
fused tricyclic
fused
Prior art date
Application number
MA055198A
Other languages
English (en)
Inventor
Michael Steven Bodnarchuk
Scott Boyd
Doyle Joseph Cassar
Jason Grant Kettle
Christopher Phillips
Kurt Gordon Pike
Iain Simpson
Oliver Ross Steward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA55198A publication Critical patent/MA55198A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA055198A 2019-03-05 2020-03-03 Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux MA55198A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813885P 2019-03-05 2019-03-05
US201962951146P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
MA55198A true MA55198A (fr) 2022-01-12

Family

ID=69740367

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055198A MA55198A (fr) 2019-03-05 2020-03-03 Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux

Country Status (23)

Country Link
US (1) US20220204527A1 (fr)
EP (1) EP3935060B1 (fr)
JP (1) JP7453989B2 (fr)
KR (1) KR20210135539A (fr)
CN (1) CN113508118B (fr)
AU (1) AU2020231045B2 (fr)
BR (1) BR112021017408A2 (fr)
CA (1) CA3131156A1 (fr)
CL (1) CL2021002296A1 (fr)
CO (1) CO2021012381A2 (fr)
CR (1) CR20210504A (fr)
DO (1) DOP2021000183A (fr)
EC (1) ECSP21073246A (fr)
IL (1) IL285761B1 (fr)
JO (1) JOP20210241A1 (fr)
MA (1) MA55198A (fr)
MX (1) MX2021010674A (fr)
PE (1) PE20220140A1 (fr)
SG (1) SG11202109451TA (fr)
TW (1) TW202100532A (fr)
UY (1) UY38602A (fr)
WO (1) WO2020178282A1 (fr)
ZA (1) ZA202106192B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020085493A1 (fr) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 Nouveau composé d'indazole ou sel de celui-ci
WO2020146613A1 (fr) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP4021444A4 (fr) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
CA3152025A1 (fr) 2019-09-24 2021-04-01 David BRIERE Polytherapies
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
WO2021108683A1 (fr) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
CN114828964B (zh) 2019-12-11 2023-11-24 伊莱利利公司 Kras g12c抑制剂
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
CA3187757A1 (fr) 2020-09-03 2022-03-24 Ethan AHLER Utilisation d'inhibiteurs de sos1 pour traiter des malignites a mutations de shp2
CN114437107A (zh) * 2020-11-06 2022-05-06 江苏先声药业有限公司 哌嗪类化合物及其应用
CN114539286B (zh) * 2020-11-24 2024-02-02 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
TW202235082A (zh) 2020-12-04 2022-09-16 美商美國禮來大藥廠 Ｋｒａｓ ｇ１２ｃ抑制劑
WO2022133345A1 (fr) 2020-12-18 2022-06-23 Erasca, Inc. Pyridones et pyrimidones tricycliques
CN117083279A (zh) * 2021-04-08 2023-11-17 基因泰克公司 氧氮杂䓬化合物及其在癌症治疗中的用途
CA3224341A1 (fr) 2021-09-01 2023-03-09 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers
TW202322819A (zh) 2021-10-22 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
TW202325298A (zh) * 2021-11-01 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN118434422A (zh) 2021-12-28 2024-08-02 阿斯利康(英国)有限公司 抗体-药物缀合物和rasg12c抑制剂的组合
WO2023168036A1 (fr) 2022-03-04 2023-09-07 Eli Lilly And Company Procédé de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs de shp2
WO2023196887A1 (fr) 2022-04-08 2023-10-12 Eli Lilly And Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318412A1 (en) * 2006-07-11 2009-12-24 Takahiro Matsumoto Tricyclic heterocyclic compound and use thereof
NO2714752T3 (fr) * 2014-05-08 2018-04-21
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3621968A1 (fr) 2017-05-11 2020-03-18 Astrazeneca AB Composés hétéroaryle inhibant des protéines ras portant la mutation g12c
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
MX2021010674A (es) 2021-09-28
EP3935060C0 (fr) 2023-11-15
EP3935060A1 (fr) 2022-01-12
CR20210504A (es) 2022-02-08
IL285761A (en) 2021-10-31
UY38602A (es) 2020-09-30
IL285761B1 (en) 2024-08-01
US20220204527A1 (en) 2022-06-30
JOP20210241A1 (ar) 2023-01-30
JP2022523981A (ja) 2022-04-27
ECSP21073246A (es) 2021-11-30
DOP2021000183A (es) 2021-09-30
AU2020231045A1 (en) 2021-10-28
KR20210135539A (ko) 2021-11-15
ZA202106192B (en) 2022-08-31
BR112021017408A2 (pt) 2022-01-18
CO2021012381A2 (es) 2021-10-20
CA3131156A1 (fr) 2020-09-10
JP7453989B2 (ja) 2024-03-21
CN113508118B (zh) 2024-07-19
EP3935060B1 (fr) 2023-11-15
PE20220140A1 (es) 2022-01-27
WO2020178282A1 (fr) 2020-09-10
SG11202109451TA (en) 2021-09-29
CL2021002296A1 (es) 2022-04-29
AU2020231045B2 (en) 2023-03-16
CN113508118A (zh) 2021-10-15
TW202100532A (zh) 2021-01-01

Similar Documents

Publication Publication Date Title
MA55198A (fr) Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux
MA52754A (fr) Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA46955A (fr) Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique
MA46452A (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA52367A (fr) Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase